Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-hodgkin lymphoma
Overview of attention for article published in Clinical Therapeutics, January 2009
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (98th percentile)
-
High Attention Score compared to outputs of the same age and source (97th percentile)
Readers on
- mendeley
- 111 Mendeley